Tiba Biotech has announced a major scientific milestone with the development of the world’s first RNA vaccine against Foot-and-Mouth Disease (FMD), demonstrating complete protection in challenge trials conducted with international partners from Australia, Canada, and Germany.
This achievement was recently featured on Landline, the Australian Broadcasting Corporation’s (ABC) flagship program covering rural and regional affairs. The October 26 episode highlighted how Tiba Biotech is preparing for regulatory approval of its breakthrough FMD vaccine — a threat that could cost Australia’s livestock sector an estimated AU $80 billion if an outbreak occurred.
“This vaccine is the equivalent for cows as penicillin was for humans.”
— Tara Moriarty, New South Wales (NSW) Minister for Primary Industries
International researchers and the NSW Department of Primary Industries and Regional Development (DPIRD) are partnering with Tiba Biotech to advance a synthetic mRNA delivery platform for emergency-use livestock vaccines. This collaboration is part of a $20 million initiative funded by the regional government and industry sponsors, including Meat & Livestock Australia (MLA) — a national research organization backed by Australian producers and the federal government.
“Our core RNA delivery technology is a bit like software, you program it for whatever disease you want to target.”
— Peter McGrath, co-founder and head of Tiba Biotech’s animal health initiative
Tiba Biotech’s RNA technology marks a new era for global livestock protection, extending to diseases such as Lumpy Skin Disease, African Swine Fever, and other viral threats across the globe. As highlighted in the ABC segment, the platform enables the rapid development of vaccines against emerging biosecurity threats that endanger rural communities and global food supply chains.
The Landline segment featuring Tiba Biotech’s emergency-use vaccine program can be viewed here and the official news release is available here.
***
About Tiba Biotech
Tiba Biotech LLC is a preclinical-stage biopharmaceutical company based in Cambridge, Massachusetts, developing next-generation RNA medicines using its proprietary RNABL™ delivery platform. Tiba’s mission is to unlock RNA’s therapeutic potential by enabling organ-targeted, safe, and potent delivery solutions to address cancer, infectious diseases, and other serious conditions. For more information about Tiba Biotech, visit www.tiba.bio, follow us on X (formally Twitter) @TibaBiotech and LinkedIn.
Media Contact:
info@tiba.bio
